Completed NA INTERVENTIONAL 4-arm NCT01175200

Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction. (DOSAPI)

Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction. A Prospective, Mono-center, Placebo- and Active Treatment-controlled, Randomized, Cross Over Study.

Sponsor: Ascopharm Groupe Novasco

Conditions Anti Platelet Effects

Interventions Clopidogrel Lansoprazole Placebo Prasugrel

Updated 5 times since 2017 Last updated: Jul 3, 2012 Started: Sep 30, 2010 Primary completion: Jul 31, 2012 Completion: Jul 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Anti Platelet Effects, this trial is completed. The trial is conducted by Ascopharm Groupe Novasco and has accumulated 5 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ascopharm Groupe Novasco
Groupe Hospitalier Pitie-Salpetriere
Medco Health Solutions, Inc.

Data source: Ascopharm Groupe Novasco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France